Acute complications of nuclear medicine: an emergency medicine perspective Authors: Mehmet Necmeddin Sutaşır, Banu Arslan, Mohamed Mukhtar Mohamed, Nihat Müjdat Hökenek Published: 2026 ABSTRACT BackgroundNuclear medicine procedures are increasingly integrated into routine clinical practice worldwide, including in low- and middle-income settings. Although radiopharmaceuticals have a well-established safety profile, the growing volume of diagnostic and therapeutic procedures means that acute adverse events, while uncommon, are encountered with sufficient frequency to present to emergency departments. Emergency physicians are often the first clinicians to assess patients with post-procedural symptoms, yet guidance tailored to emergency care remains limited. This review aims to provide an emergency medicine–focused synthesis of the incidence, clinical presentation, and acute management of adverse events associated with nuclear medicine procedures.We conducted a narrative review using a systematic search strategy across PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library, covering publications from January 2020 to December 2024. Studies reporting acute events related to radiopharmaceutical administration, including extravasation, allergic reactions, maladministration, and radiation contamination, were included. Evidence from cohort studies, surveillance registries, systematic reviews, and relevant case reports was synthesized narratively due to methodological heterogeneity.Main bodySixty-eight studies encompassing over two million radiopharmaceutical administrations were included. Diagnostic radiopharmaceutical extravasation was common when systematically assessed but rarely resulted in clinically significant harm. Severe allergic reactions and anaphylaxis were exceedingly rare. Maladministration events occurred infrequently and were predominantly associated with diagnostic procedures, with minimal patient harm in most cases. In contrast, extravasation and toxicity related to therapeutic radiopharmaceuticals, particularly high-energy beta emitters, carried greater clinical significance. Newer agents such as lutetium-177–labelled therapies demonstrated predictable toxicity profiles, with hematologic adverse events representing the primary emergency care concern.Emerging alpha-emitting theranostic agents such as actinium-225–PSMA-617 demonstrate promising efficacy but may be associated with clinically relevant xerostomia and hematologic toxicity.ConclusionAcute events related to nuclear medicine procedures are uncommon but clinically relevant in emergency practice. Diagnostic radiopharmaceuticals are generally safe and require supportive management, whereas therapeutic radiopharmaceutical complications warrant heightened vigilance and specialist consultation. Familiarity with these presentations can support timely, appropriate emergency care, particularly in settings with limited on-site nuclear medicine expertise.Supplementary InformationThe online version contains supplementary material available at 10.1186/s13550-026-01464-2. Background Nuclear medicine has become an indispensable component of modern healthcare, with approximately 40 to 50 million diagnostic and therapeutic procedures performed annually worldwide according to recent 2024 estimates [1]. In the United States alone, over 20 million nuclear medicine examinations are conducted each year, and more than 10,000 hospitals globally utilize medical radioisotopes for patient care [2]. The field continues to expand rapidly, driven by advances in hybrid imaging modalities such as positron emission tomography/computed tomography (PET/CT) and single-photon emission computed tomography/computed tomography (SPECT/CT), together with the growing use of targeted therapeutic radiopharmaceuticals in oncology [3]. Although radiopharmaceuticals have maintained an excellent safety profile over decades of clinical use, the increasing volume and complexity of procedures mean that acute adverse events continue to be encountered in clinical practice [4]. Patients experiencing adverse reactions, extravasation injuries, or concerns related to maladministration may present to emergency departments, particularly when symptoms develop after discharge or outside routine operating hours [5]. Emergency physicians therefore play an important role in the recognition and initial management of these relatively uncommon but clinically significant presentations. Recent years have seen substantial expansion in therapeutic and theranostic radiopharmaceutical applications. In 2022, the United States Food and Drug Administration approved lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617, Pluvicto) for metastatic castration-resistant prostate cancer, representing a major milestone in theranostic oncology [6]. Similar advances in peptide receptor radionuclide therapy for neuroendocrine tumors have further increased the use of targeted radionuclide therapies [7]. Theranostic approaches integrate molecular imaging and targeted radionuclide therapy using structurally related tracers, enabling individualized diagnosis, treatment selection, and response assessment [8, 9]. As these agents become more widely adopted, emergency physicians may increasingly encounter complications related to therapy-associated toxicities, extravasation, and maladministration. Despite the growing clinical relevance of these presentations, emergency medicine literature addressing acute complications of nuclear medicine remains limited. Much of the available guidance is contained within nuclear medicine or radiation safety literature and may not adequately reflect contemporary therapeutic radiopharmaceutical practice [10, 11]. This gap is particularly important given evidence suggesting that patient-reported adverse events may occur more frequently than recognized through conventional institutional surveillance systems [5]. The objective of this narrative review is to provide emergency physicians with a comprehensive, evidence-based synthesis of the incidence, clinical presentation, and acute management of complications associated with nuclear medicine procedures. Particular emphasis is placed on radiopharmaceutical extravasation, systemic adverse reactions, maladministration, radiation contamination, and the evolving toxicity profiles of newer therapeutic and theranostic agents. Methods Review design and search strategy We conducted a narrative review with systematic search methodology to synthesize current evidence on acute events in nuclear medicine practice. Given the heterogeneity of study designs, populations, and outcome definitions across this field, we determined that a narrative synthesis approach was most appropriate for integrating diverse evidence types ranging from large registry analyses to case series describing rare but clinically significant events [12]. Four major electronic databases were searched: PubMed/MEDLINE, Embase, Cochrane Library, and Scopus. The search covered publications from January 2020 through December 2024 to capture contemporary evidence, supplemented by seminal earlier works where necessary for historical context. Search terms were developed using Medical Subject Headings (MeSH) and free-text keywords combined with Boolean operators. Search domains were selected to capture both clinically significant patient complications and operational or radiation-safety events that may occasionally prompt emergency department evaluation or consultation. The primary search domains included: (radiopharmaceutical OR nuclear medicine OR radiotracer) combined with (extravasation OR adverse reaction OR anaphylaxis OR maladministration OR contamination) and (incidence OR management OR emergency). Reference lists of included articles were manually screened to identify additional relevant studies. Eligibility criteria Studies were eligible for inclusion if they reported data on the incidence, severity, management, or outcomes of acute events occurring during or shortly after radiopharmaceutical administration. We included prospective and retrospective cohort studies, systematic reviews, registry-based analyses, and national or international surveillance reports. Given the rarity of some events, particularly therapeutic radiopharmaceutical extravasation and severe allergic reactions, case reports and small case series were also included when they provided clinically relevant management information not available from larger studies [13]. We excluded studies focused exclusively on long-term radiation effects, occupational exposure data without patient-related outcomes, animal studies, conference abstracts without full-text availability, and articles published in languages other than English. Data synthesis Two authors independently reviewed titles and abstracts to enhance consistency. Data extraction was performed using a standardized form capturing study design, population characteristics, type of radiopharmaceutical, event type and incidence, severity grading, clinical presentation, management approaches, and patient outcomes. Given the heterogeneity in study designs and outcome definitions, pooled meta-analysis was not feasible; instead, incidence rates are reported as ranges reflecting variation across studies. Adverse event severity was categorized according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 when original studies used comparable grading systems. Definitions For the purposes of this review, we adopted the following operational definitions. Extravasation was defined as the inadvertent administration of radiopharmaceutical into perivascular tissue rather than the intended vascular space. Anaphylaxis was defined according to the World Allergy Organization 2020 criteria as a severe, potentially life-threatening systemic hypersensitivity reaction involving respiratory compromise, cardiovascular instability, or severe gastrointestinal symptoms [14]. Maladministration referred to the administration of an incorrect radiopharmaceutical, incorrect activity, or administration to the wrong patient. Radiation contamination was defined as the unintended deposition of radioactive material on surfaces, equipment, or personnel. Results Literature overview The database search yielded 2,847 potentially relevant citations. After removing duplicates and screening, 68 studies met inclusion criteria and were incorporated into this narrative synthesis. These comprised retrospective and prospective cohort studies, case series, systematic reviews, and registry-based surveillance reports. The included studies collectively analyzed data from over 2 million radiopharmaceutical administrations across North America, Europe, Asia, and Oceania. Study quality varied substantially, reflecting the field’s reliance on retrospective registry data and passive surveillance systems; this heterogeneity precluded formal quality scoring but is acknowledged as a limitation. A supplementary table summarizing the included studies and their primary characteristics is provided as Supplementary Material 1. Radiopharmaceutical extravasation Incidence and detection Extravasation emerged as the most frequently reported acute event in nuclear medicine, though reported incidence varies substantially depending on detection methodology. Studies relying on clinical observation alone reported rates between 3% and 8%, while those employing research-grade systematic detection methods such as topical radiation sensors documented higher rates of 15% to 23% [15, 16]. This discrepancy reflects that sensor-detected events largely represent subclinical extravasations that would go unrecognized in routine practice due to small injection volumes and absence of immediate symptoms. Emergency physicians should recognize that extravasation rates may appear higher when systematic detection methods are employed. A retrospective analysis of consecutive PET/CT examinations using standardized imaging protocols identified partial or complete tracer extravasation in approximately 15% of cases when systematically assessed [16]. The investigators noted considerable inter-institutional variability, with rates at individual centers ranging from 2.9% to over 20% depending on injection technique, operator experience, and patient-related factors such as venous access quality. Importantly, structured training programs have demonstrated the potential for substantial reductions. One multicenter initiative implementing a structured Define-Measure-Analyze-Improve-Control methodology achieved a 78% decrease in detected PET/CT extravasation rates, from 13.3% to 2.9% over 25 weeks (P < 0.001) [17, 18]. Clinical consequences and emergency relevance The clinical significance of extravasation varies dramatically depending on whether a diagnostic or therapeutic radiopharmaceutical is involved. For commonly used diagnostic agents including technetium-99 m labeled compounds, fluorine-18 fluorodeoxyglucose (18 F-FDG), and gallium-68 labeled tracers, no well-documented cases of severe or permanent tissue injury have been reported in the peer-reviewed literature, though isolated minor local reactions may occur [13]. These agents deliver relatively low radiation doses to the infiltrated tissue, and the radioactivity disperses through lymphatic drainage without causing deterministic effects. The primary clinical impact of diagnostic extravasation is on image quality and quantification. However, substantial tracer retention at the injection site may impair image interpretation, potentially resulting in misdiagnosis, delayed treatment, and subsequent patient harm. In contrast, therapeutic radiopharmaceutical extravasation presents a genuine emergency medicine concern. A systematic review examining published reports identified 39 documented cases across 28 publications [19]. Severity ranged from transient swelling and erythema to severe radiation-induced injury including moist desquamation and tissue necrosis. The most serious outcomes occurred following extravasation of high-energy beta emitters used in radiosynoviorthesis and large-molecule yttrium-90 labeled antibodies. Emergency physicians should recognize that patients presenting with progressive pain, swelling, or skin changes at an injection site following recent therapeutic nuclear medicine procedures may be experiencing radiation injury requiring specialist consultation. For lutetium-177 labeled peptide receptor radionuclide therapy and prostate-specific membrane antigen targeted treatments, no cases of radiation-induced tissue damage following extravasation have been reported to date [19]. However, long-term follow-up data remain limited, and absence of reported cases should not be interpreted as absence of risk. This favorable profile likely reflects the pharmacokinetic properties of these agents allowing relatively rapid clearance from the infiltration site, but vigilance remains appropriate. The clinical features and emergency management strategies for radiopharmaceutical extravasation are summarized in Table 1. Table 1Clinical Features and Emergency Management of Radiopharmaceutical ExtravasationRadiopharmaceuticalcategoryRisk levelClinical featuresEmergency management99mTc-labeled (MDP, sestamibi, MAA)LowUsually asymptomatic; rare minor local reactionNo specific intervention; warm compress; limb elevation18 F-FDG, 68Ga-PSMA/DOTATATELowMild local warmth possibleObservation; massage toward lymphatics; warm compress177Lu-PSMA/DOTATATELow-Moderate*Localized swelling, mild painLimb elevation; gentle massage; monitoring for 24–48 h90Y-ibritumomab, radiosynoviorthesisHighPain, erythema, progressive swellingUrgent nuclear medicine consult; consider surgical evaluation if necrosis131I-NaI (high dose therapy)Moderate-HighDelayed erythema, desquamationSpecialist referral; wound care; radiation dosimetry assessmentMDP: methylene diphosphonate; MAA: macroaggregated albumin; FDG: fluorodeoxyglucose; PSMA: prostate-specific membrane antigen. *Long-term safety data limited.** Risk classification based on theoretical dosimetry and limited clinical reports Table 1Clinical Features and Emergency Management of Radiopharmaceutical ExtravasationRadiopharmaceuticalcategoryRisk levelClinical featuresEmergency management99mTc-labeled (MDP, sestamibi, MAA)LowUsually asymptomatic; rare minor local reactionNo specific intervention; warm compress; limb elevation18 F-FDG, 68Ga-PSMA/DOTATATELowMild local warmth possibleObservation; massage toward lymphatics; warm compress177Lu-PSMA/DOTATATELow-Moderate*Localized swelling, mild painLimb elevation; gentle massage; monitoring for 24–48 h90Y-ibritumomab, radiosynoviorthesisHighPain, erythema, progressive swellingUrgent nuclear medicine consult; consider surgical evaluation if necrosis131I-NaI (high dose therapy)Moderate-HighDelayed erythema, desquamationSpecialist referral; wound care; radiation dosimetry assessmentMDP: methylene diphosphonate; MAA: macroaggregated albumin; FDG: fluorodeoxyglucose; PSMA: prostate-specific membrane antigen. *Long-term safety data limited.** Risk classification based on theoretical dosimetry and limited clinical reports Clinical Features and Emergency Management of Radiopharmaceutical Extravasation MDP: methylene diphosphonate; MAA: macroaggregated albumin; FDG: fluorodeoxyglucose; PSMA: prostate-specific membrane antigen. *Long-term safety data limited.** Risk classification based on theoretical dosimetry and limited clinical reports Anaphylaxis and systemic adverse reactions Incidence rates Radiopharmaceuticals demonstrate a favorable safety profile compared with other intravenously administered agents. Historical surveillance data from the British Nuclear Medicine Society documented adverse reaction rates of 2.5 to 3.1 per 100,000 administrations during 2007–2016 [20]. A landmark prospective multicenter study monitoring 1,024,177 radiopharmaceutical administrations between 2007 and 2011 confirmed an adverse event incidence of 2.1 per 100,000, with no hospitalizations or fatalities recorded [4]. These rates have remained relatively stable across two decades of surveillance for conventional diagnostic agents. However, more recent prospective research employing patient-reported outcome methodology suggests that traditional surveillance may underestimate true event rates. A cohort study of 1,002 patients using validated questionnaires found that 18.7% reported at least one adverse event, with 43% of these judged to be possibly or probably related to the radiopharmaceutical [5]. The calculated adverse drug reaction rate was 2.8%, substantially higher than registry-based estimates. This discrepancy arises because approximately 20% of adverse events occurred after patients had departed the nuclear medicine department and were therefore missed by conventional surveillance systems. For emergency physicians, this finding underscores that patients may present with symptoms related to recent nuclear medicine procedures that would not have been captured through institutional reporting. Clinical presentations Most adverse reactions to radiopharmaceuticals are mild and self-limiting. The predominant symptom categories include general disorders and administration site conditions (42% of patient-reported events) and nervous system manifestations (17%) [5]. Specific symptoms most frequently documented include nausea, flushing, dizziness, pruritus, urticaria, transient hypotension, and vasovagal episodes. These typically resolve within minutes to hours without specific intervention. Severe reactions including true anaphylaxis are exceedingly rare. Based on historical surveillance data, anaphylactic reactions are estimated to occur at rates below 0.1 per 100,000 administrations, though this figure derives primarily from passive reporting systems that may underascertain events [4, 20]. Modern PET radiopharmaceuticals have limited direct anaphylaxis incidence data; extrapolation from historical technetium-99 m surveillance should be made cautiously. Technetium-99 m sestamibi has been associated with isolated cases of generalized exfoliative dermatitis, angioedema, and erythema multiforme, typically manifesting 24 to 48 h post-administration [21]. The agents most commonly implicated in allergic-type reactions remain technetium-99 m labeled diphosphonates, colloids, and albumin preparations [20]. Emergency physicians should be aware that patients with known hypersensitivity to these agents or with a history of adverse reactions to radiopharmaceuticals carry elevated risk and may benefit from premedication protocols similar to those used for iodinated contrast media. Recognition patterns and structured emergency management of radiopharmaceutical adverse reactions are outlined in Table 2. Table 2Recognition and emergency management of radiopharmaceutical adverse reactionsSeverityClinical featuresEstimated incidence*Emergency managementMildNausea, flushing, dizziness, localized urticaria, metallic taste1–2 per 100,000Observation; reassurance; symptomatic careModerateGeneralized urticaria, bronchospasm (mild), hypotension (responsive)0.3–0.5 per 100,000Antihistamines; bronchodilators; IV fluids; monitoringSevere (Anaphylaxis)Laryngeal edema, severe bronchospasm, cardiovascular collapse< 0.1 per 100,000Epinephrine IM; airway management; IV fluids; vasopressors PRNDelayedErythema multiforme, exfoliative dermatitis (24–48 h post)Rare case reportsCorticosteroids; dermatology consult; supportive careIM: intramuscular; IV: intravenous; PRN: as needed. *Based on historical surveillance data; actual rates may be higher Table 2Recognition and emergency management of radiopharmaceutical adverse reactionsSeverityClinical featuresEstimated incidence*Emergency managementMildNausea, flushing, dizziness, localized urticaria, metallic taste1–2 per 100,000Observation; reassurance; symptomatic careModerateGeneralized urticaria, bronchospasm (mild), hypotension (responsive)0.3–0.5 per 100,000Antihistamines; bronchodilators; IV fluids; monitoringSevere (Anaphylaxis)Laryngeal edema, severe bronchospasm, cardiovascular collapse< 0.1 per 100,000Epinephrine IM; airway management; IV fluids; vasopressors PRNDelayedErythema multiforme, exfoliative dermatitis (24–48 h post)Rare case reportsCorticosteroids; dermatology consult; supportive careIM: intramuscular; IV: intravenous; PRN: as needed. *Based on historical surveillance data; actual rates may be higher Recognition and emergency management of radiopharmaceutical adverse reactions IM: intramuscular; IV: intravenous; PRN: as needed. *Based on historical surveillance data; actual rates may be higher Maladministration events Incidence and causative factors Data from the Australian Radiation Incident Register, a mandatory national reporting system, documented 149 maladministrations over a five-year period, yielding an estimated incidence of 5.8 per 100,000 nuclear medicine procedures (95% CI: 5.0-6.9) [22]. Analysis of causative factors revealed that nearly half of all events (48%) originated from errors during radiopharmaceutical preparation or dispensing, typically involving selection of an incorrect lyophilized kit or mislabeled vial. The remaining cases arose from administering the wrong prepared radiopharmaceutical due to momentary inattention (18.1%), procedure or equipment failures including unrecognized extravasation (16.8%), misinterpretation of the referring physician’s request (8.7%), and wrong patient identification (8.7%). Temporal analysis revealed that 21% of incidents occurred in clusters, predominantly linked to errors during bulk radiopharmaceutical dispensing, suggesting that systemic process failures rather than isolated individual practitioner mistakes drive a substantial proportion of events [23, 24]. This pattern has important implications for quality improvement, emphasizing the need for system-level safeguards including barcode verification, independent double-checks, and standardized timeout procedures. Patient outcomes and emergency implications The clinical consequences of maladministration depend critically on whether diagnostic or therapeutic agents are involved. For diagnostic procedures, which account for approximately 98% of all reported maladministrations, clinically significant patient harm is uncommon. The mean effective radiation dose from diagnostic maladministrations was 7.9 mSv (range: 0.015-45 mSv), comparable to that from a standard computed tomography scan [22]. In the Australian registry analysis, no patient harm occurred in 98.6% of diagnostic maladministration cases. Therapeutic maladministrations, while less frequent, carry more serious potential implications. The Australian registry documented two cases of likely unintended organ injury following therapeutic radiopharmaceutical errors [22]. Emergency physicians may encounter patients who present with concerns about potential maladministration, particularly following media coverage of nuclear medicine incidents. In such cases, it is important to obtain details of the procedure performed, contact the nuclear medicine facility for clarification, and provide appropriate reassurance when diagnostic agents are involved while acknowledging that complete absence of risk cannot be guaranteed. For therapeutic maladministration, radiation safety officer involvement and potential dosimetry assessment are warranted. A classification framework and risk mitigation strategies for nuclear medicine maladministration events are presented in Table 3. Table 3Classification of nuclear medicine maladministrationsError typeFrequencyRoot causesRisk mitigationWrong radiopharmaceutical prepared48%Kit mislabeling; similar packagingBarcode verification; independent double-checkWrong syringe administered18.1%Workflow interruption; inattentionPatient-syringe matching protocolProcedure/equipment failure16.8%Undetected extravasation; device malfunctionPost-injection imaging; equipment QAWrong procedure performed8.7%Request misinterpretation; poor communicationTimeout verification; electronic orderingWrong patient8.7%Inadequate patient identificationTwo-identifier verification; wristband scanningQA: quality assurance. Data from Australian Radiation Incident Register [22] Table 3Classification of nuclear medicine maladministrationsError typeFrequencyRoot causesRisk mitigationWrong radiopharmaceutical prepared48%Kit mislabeling; similar packagingBarcode verification; independent double-checkWrong syringe administered18.1%Workflow interruption; inattentionPatient-syringe matching protocolProcedure/equipment failure16.8%Undetected extravasation; device malfunctionPost-injection imaging; equipment QAWrong procedure performed8.7%Request misinterpretation; poor communicationTimeout verification; electronic orderingWrong patient8.7%Inadequate patient identificationTwo-identifier verification; wristband scanningQA: quality assurance. Data from Australian Radiation Incident Register [22] Classification of nuclear medicine maladministrations QA: quality assurance. Data from Australian Radiation Incident Register [22] Radiation contamination events Radioactive material spills and contamination incidents occur regularly in nuclear medicine departments but rarely constitute true emergencies. The literature distinguishes between minor spills, typically defined as involving less than 370 kBq (10 µCi) of radioactivity confined to a small area without personnel contamination, and major spills requiring evacuation and professional decontamination response [25]. Minor spills are managed routinely by trained nuclear medicine staff using established protocols involving containment with absorbent materials, systematic decontamination working from periphery to center, and radiation survey confirmation. A systematic review of nuclear medicine safety incidents identified three primary causative categories: inadequate handling of radionuclides, equipment malfunction, and loss or misplacement of radioactive sources [10]. Personnel skin or clothing contamination, while uncommon, requires immediate notification of radiation safety personnel and prompt decontamination using tepid water and mild soap, avoiding abrasive scrubbing that could drive contamination deeper into the skin. Emergency physicians should recognize that true radiation emergencies in nuclear medicine settings are exceptional and typically occur only when contamination events are complicated by fire, explosion, or serious traumatic injury. For most diagnostic radiopharmaceutical procedures, radiation exposure risk to emergency personnel remains low, and standard precautions are generally sufficient even in the presence of bodily fluid contamination [10, 25]. Appropriate patient assessment and stabilization should therefore not be delayed because of concerns regarding radiation exposure. Patients receiving therapeutic radionuclide treatments may require additional radiation-safety considerations, particularly when contamination from bodily fluids is suspected. When patients present to the emergency department following potential radiation exposure from nuclear medicine procedures, the priority remains standard medical assessment and stabilization. For diagnostic radiopharmaceuticals with short half-lives, external contamination poses minimal risk to healthcare workers, and standard precautions are adequate. Patients who have received therapeutic radiopharmaceuticals may require specific precautions, and consultation with radiation safety officers or medical physicists is advisable when the exposure circumstances are unclear. Therapeutic radiopharmaceuticals: acute toxicity profiles The therapeutic radiopharmaceutical landscape has expanded substantially with recent regulatory approvals, most notably lutetium-177 vipivotide tetraxetan (177Lu-PSMA-617, Pluvicto) for metastatic castration-resistant prostate cancer in March 2022. These agents present unique considerations for emergency physicians who may encounter patients during or following treatment courses. Data from the phase III VISION trial demonstrate that most adverse events associated with 177Lu-PSMA-617 therapy are mild to moderate in severity [6]. The most frequently reported effects include xerostomia (dry mouth) in approximately 39% of patients, typically grade 1–2 and manageable symptomatically. Hematologic toxicity represents the primary safety concern, with grade 3 or higher anemia occurring in 12.9%, thrombocytopenia in 7.9%, and lymphopenia in 7.8% of patients [6]. Fatigue affects approximately 43% of patients, while nausea occurs in 35% but is usually self-limiting. The toxicity profile of therapeutic radiopharmaceuticals varies according to radionuclide energy characteristics and biodistribution properties [26]. The PSMAfore trial, comparing 177Lu-PSMA-617 with androgen receptor pathway inhibitor change in taxane-naive metastatic castration-resistant prostate cancer, demonstrated that exposure-adjusted rates of grade 3 or higher adverse events were 60.8 per 100 patient-treatment years with 177Lu-PSMA-617, compared with 85.1 per 100 patient-treatment years with alternative systemic therapy [27]. This comparison provides important context: while therapeutic radiopharmaceuticals carry meaningful toxicity, their adverse event profiles are comparable to or more favorable than alternative systemic treatments in appropriate patient populations. Emerging alpha-emitting radiopharmaceuticals such as actinium-225–PSMA-617 demonstrated significant antitumor activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who had progressed after lutetium-177–PSMA therapy, supporting their potential role as promising salvage treatment options. However, treatment was associated with notable toxicities, particularly xerostomia and hematologic adverse effects, highlighting the need for careful patient selection and toxicity monitoring [28]. Emergency physicians should be aware that patients undergoing lutetium-177 therapies may present with cytopenias requiring transfusion support, infection related to myelosuppression, or renal function changes. Extended therapy beyond standard protocols has not revealed new safety signals, though hematologic parameters warrant close monitoring throughout treatment [29]. Patients with extensive bone metastases may be at higher risk for hematologic toxicity due to compromised marrow reserve and direct radiation effects on residual hematopoietic tissue [30]. Key acute toxicity considerations relevant to emergency department assessment are summarized in Table 4. Table 4Acute toxicity profile of 177Lu-PSMA-617 therapy: emergency department considerationsAdverse eventAny gradeGrade ≥ 3ED management considerationsFatigue43.1%5.5%Rule out other causes; supportive careXerostomia38.8%0.2%Symptomatic; saliva substitutes; hydrationNausea35.3%0.4%Antiemetics; hydration; electrolyte monitoringAnemia31.8%12.9%Transfusion if symptomatic; evaluate for bleedingThrombocytopenia17.2%7.9%Bleeding precautions; platelet transfusion PRNLymphopenia23.4%7.8%Infection workup if febrile; consider prophylaxisED: emergency department; PRN: as needed. Data from VISION trial [6] Table 4Acute toxicity profile of 177Lu-PSMA-617 therapy: emergency department considerationsAdverse eventAny gradeGrade ≥ 3ED management considerationsFatigue43.1%5.5%Rule out other causes; supportive careXerostomia38.8%0.2%Symptomatic; saliva substitutes; hydrationNausea35.3%0.4%Antiemetics; hydration; electrolyte monitoringAnemia31.8%12.9%Transfusion if symptomatic; evaluate for bleedingThrombocytopenia17.2%7.9%Bleeding precautions; platelet transfusion PRNLymphopenia23.4%7.8%Infection workup if febrile; consider prophylaxisED: emergency department; PRN: as needed. Data from VISION trial [6] Acute toxicity profile of 177Lu-PSMA-617 therapy: emergency department considerations ED: emergency department; PRN: as needed. Data from VISION trial [6] Discussion Key findings and clinical implications This narrative review synthesizes contemporary evidence on acute events in nuclear medicine with specific focus on implications for emergency medicine practice. Our findings reveal several key insights that warrant emphasis. First, radiopharmaceuticals demonstrate a favorable safety profile when compared with other intravenously administered agents. The adverse reaction rate of 2.1 to 3.1 per 100,000 administrations documented through historical surveillance systems represents one of the lowest incidences among injectable pharmaceutical agents [4, 20]. However, prospective patient-reported outcome studies suggest actual event rates may be higher, with 2.8% of patients experiencing adverse drug reactions when systematically queried [5]. This discrepancy has important implications for emergency practice, as patients may present with symptoms attributed to recent nuclear medicine procedures that would not have been captured through traditional institutional reporting. Second, the clinical significance of radiopharmaceutical extravasation varies dramatically by agent category. For diagnostic tracers, extravasation is common when systematically sought (incidence 3–23% depending on detection methodology) and is rarely associated with severe permanent tissue injury [13, 15, 31]. However, impaired image quality and altered tracer quantification may contribute to diagnostic inaccuracies, delayed treatment, and potential patient harm in some cases. Emergency physicians can generally reassure patients and families that diagnostic extravasation requires only supportive measures. In contrast, therapeutic radiopharmaceutical extravasation represents a genuine emergency medicine concern, with documented cases of tissue necrosis requiring surgical intervention, particularly with high-energy beta emitters [19]. The growing adoption of theranostic agents also has important clinical implications. In these settings, complications such as extravasation or maladministration may affect not only patient safety but also diagnostic interpretation, dosimetric accuracy, and subsequent therapeutic decision-making [8, 9]. Third, our analysis of maladministration data reveals that the majority of errors occur during diagnostic procedures and clinically significant harm is uncommon in this context. The mean effective radiation dose from diagnostic maladministrations (7.9 mSv) is comparable to that from a standard CT scan [22]. However, this should not minimize the importance of appropriate risk communication with patients, as any unintended radiation exposure merits acknowledgment and explanation. Therapeutic maladministrations, while less common, carry more serious potential implications and warrant nuclear medicine specialist consultation and potential dosimetry assessment. Therapeutic radiopharmaceuticals: emerging challenges The expanding use of therapeutic radiopharmaceuticals introduces new considerations for emergency medicine. Data from the VISION trial demonstrate that 177Lu-PSMA-617 therapy produces predictable toxicity patterns that emergency physicians should recognize [6, 11]. Hematologic toxicity represents the primary safety concern, with clinically significant anemia, thrombocytopenia, and lymphopenia occurring in a meaningful minority of patients. Emergency presentations may include symptomatic anemia requiring transfusion, thrombocytopenic bleeding, or infections related to treatment-induced immunosuppression. Importantly, comparative data from the PSMAfore trial indicate that the exposure-adjusted rate of serious adverse events with 177Lu-PSMA-617 is actually lower than with alternative systemic therapies in the same patient population [27, 32]. This context is valuable when counseling patients and families about treatment-related adverse events. Emergency physicians should be aware that patients with extensive bone metastases may be at higher risk for hematologic toxicity due to compromised marrow reserve [30, 33]. Potential toxicity related to radiometabolites, particularly in first-in-human theranostic radiopharmaceutical studies, remains an emerging area of investigation with currently limited clinical evidence, warranting continued pharmacovigilance as novel agents enter clinical practice [8, 9]. Practical emergency department approach Based on our synthesis of the evidence, we propose a structured approach for emergency department evaluation of patients with concerns related to nuclear medicine procedures. The initial assessment should establish the type of radiopharmaceutical administered (diagnostic versus therapeutic), the time interval since administration, and the specific symptoms prompting presentation. For patients with localized symptoms at an injection site, distinguishing between routine post-injection findings and true extravasation injury requires attention to clinical trajectory; progressive pain, swelling, or skin changes developing over hours to days following therapeutic radiopharmaceutical administration should prompt specialist consultation. Systemic symptoms following radiopharmaceutical administration are most commonly mild and self-limiting. True anaphylaxis, while exceedingly rare, should be managed according to standard protocols including intramuscular epinephrine, airway management, and circulatory support as indicated [14]. For patients undergoing therapeutic radiopharmaceutical treatment who present with cytopenias, the approach should parallel that for chemotherapy-induced myelosuppression, with transfusion support, infection evaluation, and coordination with the treating oncology or nuclear medicine team. Limitations Several limitations of this review merit acknowledgment. The narrative synthesis approach, while appropriate given the heterogeneity of available evidence, does not permit the quantitative precision of formal meta-analysis. Study quality varied substantially across included sources, ranging from well-designed prospective cohort studies to passive surveillance registries subject to underreporting; formal quality scoring was not performed due to this heterogeneity. Greater interpretative weight was given to large registries, prospective studies, and randomized trials. Incidence estimates derived from surveillance registries likely underestimate true event rates, as suggested by the discrepancy between registry-based and patient-reported adverse event frequencies [5]. Geographic variation in regulatory reporting requirements complicates cross-jurisdictional comparisons. The rapid evolution of the therapeutic radiopharmaceutical landscape means that safety data for newer agents remains more limited than for established diagnostic tracers, and long-term follow-up is ongoing. Additionally, the emergency medicine literature specifically addressing nuclear medicine events is sparse, necessitating extrapolation from nuclear medicine and radiation safety publications. Finally, this review focused on acute events; long-term radiation effects were beyond our scope. Future directions Several areas warrant further investigation. Prospective studies examining patient presentations to emergency departments following nuclear medicine procedures would help characterize the spectrum and frequency of encounters in emergency practice. Development of validated clinical decision support tools for emergency physicians encountering potential radiopharmaceutical adverse events could enhance recognition and appropriate triage. As therapeutic radiopharmaceutical indications continue to expand, ongoing pharmacovigilance with specific attention to acute toxicity patterns will be essential. Finally, educational initiatives targeting emergency medicine trainees and practitioners regarding nuclear medicine safety would address an evident knowledge gap. Conclusion Acute events in nuclear medicine, while individually uncommon, occur with sufficient frequency across the millions of annual procedures to warrant emergency physician familiarity. Diagnostic radiopharmaceuticals maintain a favorable safety profile, with extravasation requiring only supportive management and systemic adverse reactions typically being mild and self-limiting. Therapeutic radiopharmaceutical extravasation and adverse events carry more significant clinical implications and benefit from specialist consultation. The expanding use of targeted radionuclide therapies introduces new toxicity patterns, particularly hematologic, that emergency physicians should recognize. A structured approach emphasizing distinction between diagnostic and therapeutic agents, attention to clinical trajectory, and appropriate specialist involvement enables effective emergency management of these relatively rare but clinically important presentations. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1. Supplementary Material 1. Supplementary Material 2. Supplementary Material 2.